[go: up one dir, main page]

AU2018202623A1 - Oxalate salts of Teneligliptin and solvates thereof, intermediates, process of prepration and markers thereof - Google Patents

Oxalate salts of Teneligliptin and solvates thereof, intermediates, process of prepration and markers thereof Download PDF

Info

Publication number
AU2018202623A1
AU2018202623A1 AU2018202623A AU2018202623A AU2018202623A1 AU 2018202623 A1 AU2018202623 A1 AU 2018202623A1 AU 2018202623 A AU2018202623 A AU 2018202623A AU 2018202623 A AU2018202623 A AU 2018202623A AU 2018202623 A1 AU2018202623 A1 AU 2018202623A1
Authority
AU
Australia
Prior art keywords
oxalate
teneligliptin
salt
hydrate
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018202623A
Other languages
English (en)
Inventor
Shekhar Bhaskar Bhirud
Rajesh Kumar DWIVEDI
Suresh Mahadev Kadam
Shrikrishna Kantilal KALE
Bipin Parsottam Kansagra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glenmark Pharmaceuticals Ltd
Original Assignee
Glenmark Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63039388&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018202623(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glenmark Pharmaceuticals Ltd filed Critical Glenmark Pharmaceuticals Ltd
Publication of AU2018202623A1 publication Critical patent/AU2018202623A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2018202623A 2017-02-03 2018-02-02 Oxalate salts of Teneligliptin and solvates thereof, intermediates, process of prepration and markers thereof Abandoned AU2018202623A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201721004095 2017-02-03
IN201721004095 2017-02-03
PCT/IB2018/050652 WO2018142327A1 (fr) 2017-02-03 2018-02-02 Sels d'oxalate de ténéligliptine et solvates de ceux-ci, intermédiaires, procédé de préparation

Publications (1)

Publication Number Publication Date
AU2018202623A1 true AU2018202623A1 (en) 2018-08-23

Family

ID=63039388

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018202623A Abandoned AU2018202623A1 (en) 2017-02-03 2018-02-02 Oxalate salts of Teneligliptin and solvates thereof, intermediates, process of prepration and markers thereof
AU2018202960A Abandoned AU2018202960A1 (en) 2017-02-03 2018-02-02 Formulations comprising oxalate salts of Teneligliptin and solvates thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018202960A Abandoned AU2018202960A1 (en) 2017-02-03 2018-02-02 Formulations comprising oxalate salts of Teneligliptin and solvates thereof

Country Status (10)

Country Link
JP (2) JP2019508385A (fr)
KR (2) KR20180099635A (fr)
CN (2) CN108884089A (fr)
AU (2) AU2018202623A1 (fr)
BR (2) BR112018010759A2 (fr)
EA (1) EA039402B1 (fr)
MX (2) MX2018006005A (fr)
RU (2) RU2742418C1 (fr)
TW (2) TW201831473A (fr)
WO (2) WO2018142334A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020209350A1 (fr) * 2019-04-12 2020-10-15 田辺三菱製薬株式会社 Comprimé oral à désintégration rapide pour le traitement du diabète
CN110028496A (zh) * 2019-04-26 2019-07-19 梯尔希（南京）药物研发有限公司 一种特力利汀相关杂质的合成方法
WO2021053564A1 (fr) * 2019-09-17 2021-03-25 Glenmark Pharmaceuticals Limited Composition pharmaceutique comportant de la rémogliflozine ou un sel ou un ester de celle-ci et de la ténéligliptine ou un sel de celle-ci
KR20210121421A (ko) 2020-03-30 2021-10-08 코오롱생명과학 주식회사 테네리글리프틴 2.5브롬화수소산염 무정형의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI319322B (en) * 2003-11-13 2010-01-11 Ono Pharmaceutical Co Frozen-dried preperation containing prostaglandin
EP2602259A3 (fr) * 2005-02-18 2014-09-10 Mitsubishi Tanabe Pharma Corporation Sel d'un dérivé de proline, solvate de celui-ci et son procédé de production
MX2011008416A (es) * 2009-02-13 2011-09-08 Boehringer Ingelheim Int Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
PH12012501037A1 (en) * 2009-11-27 2013-01-14 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
US9572806B2 (en) * 2009-12-18 2017-02-21 Mitsubishi Tanabe Pharma Corporation Elution-stabilized preparation
US9518048B2 (en) * 2012-08-31 2016-12-13 Glenmark Pharmaceuticals Limited Process for the preparation of teneligliptin
JP6088872B2 (ja) * 2013-03-22 2017-03-01 サラヤ株式会社 ラクトン型ソホロリピッドの分解が抑制されたソホロリピッド粉末
JP5922310B2 (ja) * 2013-07-25 2016-05-24 株式会社三和化学研究所 医薬製剤
WO2015019238A1 (fr) * 2013-08-06 2015-02-12 Ranbaxy Laboratories Limited Procédé pour la préparation de (5s)-5-(1,3-thiazolidine-3-yl-carbonyl)pyrrolidin-3-one n-protégée
CN104650065A (zh) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 一种替格列汀化合物
WO2015132679A1 (fr) * 2014-03-05 2015-09-11 Glenmark Pharmaceuticals Ltd Compositions de ténéligliptine
WO2015173779A1 (fr) * 2014-05-16 2015-11-19 Micro Labs Limited Procédé de préparation de teneliglipin et nouveaux intermédiaires correspondants
CN105294673B (zh) * 2014-06-18 2018-04-13 四川科伦药物研究院有限公司 一种氢溴酸替格列汀的合成方法
US20170319539A1 (en) * 2014-10-01 2017-11-09 Mylan Laboratories Ltd. Amorphous Empagliflozin
WO2016104643A1 (fr) * 2014-12-25 2016-06-30 田辺三菱製薬株式会社 Préparation solide destinée au traitement du diabète

Also Published As

Publication number Publication date
KR20180100554A (ko) 2018-09-11
TW201834655A (zh) 2018-10-01
AU2018202960A1 (en) 2018-08-23
RU2742418C1 (ru) 2021-02-05
BR112018010759A2 (pt) 2018-12-04
TW201831473A (zh) 2018-09-01
CN108697707A (zh) 2018-10-23
JP2019508385A (ja) 2019-03-28
WO2018142334A1 (fr) 2018-08-09
MX2018006005A (es) 2019-05-16
EA201992376A1 (ru) 2020-03-23
MX2018006006A (es) 2019-05-16
EA039402B1 (ru) 2022-01-24
WO2018142327A1 (fr) 2018-08-09
JP2019512460A (ja) 2019-05-16
BR112018010748A2 (pt) 2018-12-04
CN108884089A (zh) 2018-11-23
KR20180099635A (ko) 2018-09-05
RU2018120216A (ru) 2021-05-07

Similar Documents

Publication Publication Date Title
EP2909191B1 (fr) Système cristallin multicomposant comprenant du nilotinib et des formateurs de co-cristal sélectionnés
US9440959B2 (en) Process for the preparation of nilotinib
KR102442536B1 (ko) 리나글립틴 결정형 및 이의 제조방법
US20230219892A1 (en) Forms and compositions of a beta adrenergic agonist
AU2018202623A1 (en) Oxalate salts of Teneligliptin and solvates thereof, intermediates, process of prepration and markers thereof
EP3022209B1 (fr) Sel de potassium de dolutegravir
WO2016131431A1 (fr) Formes solides d'empagliflozine
WO2022033380A1 (fr) Composé agoniste du récepteur mor, son procédé de préparation et son utilisation
US20030191347A1 (en) Venlafaxine base
EP2626355B1 (fr) Procédé de préparation d'hydrochlorure de nilotinib
US20160176832A1 (en) Crystalline forms of neurotrophin mimetic compounds and their salts
US11225467B2 (en) Crystalline forms of neurotrophin mimetic compounds and their salts
CN106831799A (zh) 羟基苯乙烯吡啶曼尼希碱类化合物、其制备方法和用途
US7393977B2 (en) Dicarboxylic acid salt of sibutramine
US10519150B2 (en) Salts of morpholine derivative, crystal forms thereof, processes for producing the same, pharmaceutical compositions including the same, and use thereof
AU2012277403A1 (en) Novel salts of sitagliptin
WO2005030698A1 (fr) Procede de preparation de voglibose
EP3650444B1 (fr) Sel et polymorphe de composé benzopyrimidinone, composition pharmaceutique et utilisation associée
US8569289B2 (en) Fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate, crystalline forms thereof, preparation thereof and therapeutic use thereof
WO2024125361A1 (fr) Forme solide d'un composé phénylsulfonamide n-substitué
WO2022224269A1 (fr) Co-cristaux, sels et formes solides de niraparib
WO2025124571A1 (fr) Antagoniste du récepteur de nmda et son utilisation
WO2025067477A1 (fr) Cyclopeptide d'acinetobacter baumannii et son utilisation
WO2021208850A1 (fr) Dérivé de nitroimidazole, son procédé de préparation et son utilisation
KR20200068667A (ko) 고체 형태의 스테모스피로닌 및 이의 염

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted